In a study by Ji (24)(Table 1) and colleagues, which involved 109 EGFR ex20ins NSCLC patients, 39 patients received platinum-based chemotherapy, achieving an ORR of 43%, a mPFS of 6.9 months, and a mOS of 31.0 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.